RedHill Biopharma Sells Stomach Treatment Stake for 18 Million Dollars

2026-08-31 companies

Raleigh, Monday, 31 August 2026.
On August 31, 2026, RedHill Biopharma secured $18 million in upfront cash by selling its 70% stake in Talicia to Apotex, providing vital liquidity to fund new acquisitions.

Transaction Overview and Immediate Liquidity

On August 31, 2026, RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the divestment of its 70% stake in the Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) [1][3]. The agreement secures an upfront cash payment of $18 million for RedHill, providing immediate liquidity to the specialty biopharmaceutical company [2][4]. Beyond the initial payment, the deal structure includes potential contingent payments of up to $35 million based on worldwide net sales milestones [3][5]. The total potential value of the transaction, combining upfront and milestone payments, amounts to 53 million dollars [1][6]. This capital injection is designed to strengthen RedHill’s balance sheet and fund subsequent commercial expansion efforts [7][8].

Consolidation of Ownership Under Apotex

This transaction completes Apotex’s consolidation of ownership over Talicia, a treatment for H. pylori infection [1][2]. Prior to this agreement, Apotex had acquired Cumberland Pharmaceuticals Inc.’s U.S. branded business, which included a 30% ownership stake in Talicia [4][8]. With the acquisition of RedHill’s remaining 70% interest, Apotex now holds full ownership of the asset [2][5]. RedHill Chief Executive Officer Dror Ben-Asher stated that Apotex is the right home to grow Talicia globally given its proven capabilities [3][7]. The deal also includes a five-year non-compete covenant for RedHill regarding the Talicia product in the U.S. and its territories [7][8].

Financial Context and Strategic Risks

The divestment occurs against a backdrop of financial distress for RedHill, which reports a market capitalization of approximately $4 million [6][7]. Analysis indicates the company has a GF Score™ of 25/100, with financial strength ranked at 2/10 [6]. The upfront payment of $18 million significantly exceeds the company’s current market valuation, highlighting the importance of the asset sale [6][7]. However, risks remain regarding the company’s ability to achieve operational profitability and the potential insufficiency of proceeds to fund all strategic plans [2][8]. Additionally, the company faces uncertainty regarding Nasdaq listing compliance and the collection of other judgments [2].

Future Pipeline and Commercial Focus

RedHill intends to utilize the proceeds to scale its existing gastrointestinal (GI) commercial franchise and acquire new, FDA-approved product opportunities [1][3]. The company’s pipeline includes candidates such as opaganib for Ebola virus disease control and RHB-204 for Crohn’s disease [2][8]. Management aims to accelerate the path toward operational profitability through these targeted acquisitions and expansions [3][7]. A Transition Services Agreement (TSA) will support the handover, lasting an initial six months with an option to extend [7][8]. The proportion of the total potential deal value secured upfront is 33.962% of the maximum consideration [1][6].

Sources

RedHill Biopharma Apotex